Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

COVID-19 tests boost Roche sales but demand expected to weaken

Stock MarketsJul 22, 2021 10:50AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A sign at a diagnostics site for Swiss pharmaceutical giant Roche is seen, in Burgess Hill, Britain, October 7, 2020. REUTERS/Peter Nicholls

By Michael Shields

ZURICH (Reuters) -Swiss drugmaker Roche said on Thursday that strong demand for COVID-19 tests had helped it rebound from a weak start to the year, as it posted better-than-expected sales for the first half.

However, the Basel-based company flagged an anticipated slowdown in demand for the tests, which have helped it fare better than some drugmakers as the number of routine hospital visits and demand for other medicines fell during the pandemic.

"As expected, demand for COVID-19 tests peaked in the second quarter and is likely to decrease in the second half of the year (although this) depends on how the pandemic develops," Chief Executive Severin Schwan said on a call with reporters, adding that there were still significant uncertainties.

Overall sales in the six months to June rose by 8% at constant currency rates to 30.71 billion Swiss francs ($33.48 billion) with core earnings up 6% to 10.56 francs per share. Analysts on average had expected sales of 29.93 billion francs and earnings of 10.10 francs per share, according to Jefferies (NYSE:JEF).

Roche's shares were down 1.6% to 350.15 Swiss francs by 1204 GMT, the biggest decliner on the European pharmaceuticals index.

Strong momentum in other routine testing also boosted sales at the diagnostics division, which masked a 3% decline in pharmaceutical sales in the first six months.

ZKB analysts acknowledged that turnover was "significantly" better than expected, but said the lift from diagnostics was more likely to be considered a "flash in the pan".

Roche offers tests for everything from active COVID-19 infections to the antibodies that document immunity after somebody has been infected or vaccinated.

It is also in discussions with U.S. authorities over the use of its Gantenerumab drug as a potential treatment for Alzheimer's disease, which if approved could see it become a blockbuster.

Roche, which expects to increase its dividend this year, maintained its forecast for 2021 sales to grow at a low- to mid-single-digit rate at constant exchange rates, with core earnings per share growing by a similar amount.

"This virus will stay with us, it will continue to mutate, and as such there will be a continued need for vaccines, for new vaccines and boosters, as well as tests and medicines," CEO Schwan said.

JPMorgan (NYSE:JPM) analysts, however, said the move to leave guidance unchanged after a strong first-half performance could be seen as conservative.

($1 = 0.9174 Swiss francs)

COVID-19 tests boost Roche sales but demand expected to weaken
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email